Characteristics and summary of diagnostic FCM in all LGw/oRS patients
. | . | . | . | . | FCM parameters . | . | . | . | ||
|---|---|---|---|---|---|---|---|---|---|---|
| Patient no. . | Age, y/sex . | WHO classification . | IPSS . | Cytogenetics . | Stage I hematogones* . | CD34+ myeloblasts* . | Antigens on CD34+ myeloblasts for which expression (RMFI) was outside RRs . | FCM score . | ||
| 1 | 40/M | MDS-U | Low | 46,XY[20] | - | - | None | 0 | ||
| 2 | 70/M | MDS-U | Int-1 | 46,XY[20] | - | - | None | 0 | ||
| 3 | 86/M | RCMD | Int-1 | 46,XY[20] | - | - | None | 0 | ||
| 4 | 76/F | NA | Int-1 | 47,XX,+8[3]/46,XX[47] | + | - | None | 1 | ||
| 5 | 54/F | NA | Int-1 | 46,XX,t(6;7)(q21;p22),del(20)(q11)[9]/46,XX[11] | + | - | None | 1 | ||
| 6 | 37/M | RCMD | Int-1 | 46,XY[20] | - | - | CD56, CD13 | 2 | ||
| 7 | 77/M | RA | Int-1 | 45,X,-Y[4]/46,X,-Y,+8[16] | + | - | CD117 | 2 | ||
| 8 | 78/M | RA | Low | 46,XY,del(20)(q11)[2]/46,XY[18] | + | - | CD117 | 2 | ||
| 9 | 84/M | RCMD | Int-1 | 46,XY[20] | + | - | CD13 | 2 | ||
| 10 | 79/M | RA | Int-1 | 46,XY,del(20)(q11)[10]/47,XY,del(20)(q11), +22[1]/46,XY[9] | - | - | CD56, CD113 | 2 | ||
| 11 | 75/F | RCMD | Int-1 | 47,XX,+8[17]/47,XX,+8,del(13)(q12q14)[3] | + | - | CD4 | 2 | ||
| 12 | 75/F | RA | Int-1 | 46,XX,t(1;2)(q?41;q?31)[18]/46,XX[2] | + | - | CD56, CD15 | 3 | ||
| 13 | 82/M | MDS-U | Low | 46,XY[20] | - | - | CD11b, CD117, CD133 | 3 | ||
| 14 | 80/M | RCMD | Int-1 | 46,XY[20] | + | + | CD117 | 3 | ||
| 15 | 81/M | RCMD | Int-1 | 46,XY,del(20)(q11)[20] | + | - | CD56, CD15 | 3 | ||
| 16 | 74/F | RCMD | Int-1 | 46,XX[20] | - | - | CD56, CD15, CD33 | 3 | ||
| 17 | 78/M | RCMD | Int-1 | 46,XY,inv(6)(p23;q15)[20] | + | - | CD13, CD117 | 3 | ||
| 18 | 39/F | RA | Low | 46,XX[20] | + | - | CD56, CD15, CD33 | 4 | ||
| 19 | 69/M | RCMD | Int-2 | 46,XY,+1,der(1;7)(q10;p10)[6]/45,X,-Y[2]/46,XY[9] | - | - | CD4, CD13, CD117, CD133 | 4 | ||
| 20 | 85/F | RCMD | Int-1 | 46XX,add(18)(p11)[19]/46XX,i(17)(q10),add(18)(p11)[1] | + | + | CD13, CD117 | 4 | ||
| 21 | 75/M | RCMD | Int-1 | 47,XY,+13[2]/46,XY[18] | + | - | CD13, CD117, CD133 | 4 | ||
| 22 | 57/F | RCMD | NA | No metaphases | + | - | CD15, CD33, CD117, CD133 | 5 | ||
| 23 | 48/M | RA | Int-1 | 47,XX,+8[20] | + | - | CD4, CD13, CD15, CD133 | 5 | ||
| 24 | 73/F | RA | Low | 46,XX[20] | - | + | CD4, CD11b, CD15, CD33 | 5 | ||
| 25 | 70/M | RCMD | Int-1 | 46,XY,+1,der(1;7)(q10;p10)[9]/46,XY[11] | + | + | CD4, CD13, CD117 | 5 | ||
| 26 | 61/M | RCMD | Int-2 | 46,XY,+1,der(1;7)(q10;p10)[10]/46,X,del(Y)(q12),+1,der(1;7)(q10;p10)[5] | + | + | CD4, CD11b, CD13, CD15 | 6 | ||
| 27 | 64/F | RA | Int-2 | 45,XX,-7,inc[3]/46,XX[17] | + | + | CD56, CD11b, CD15, CD33, CD117 | 7 | ||
. | . | . | . | . | FCM parameters . | . | . | . | ||
|---|---|---|---|---|---|---|---|---|---|---|
| Patient no. . | Age, y/sex . | WHO classification . | IPSS . | Cytogenetics . | Stage I hematogones* . | CD34+ myeloblasts* . | Antigens on CD34+ myeloblasts for which expression (RMFI) was outside RRs . | FCM score . | ||
| 1 | 40/M | MDS-U | Low | 46,XY[20] | - | - | None | 0 | ||
| 2 | 70/M | MDS-U | Int-1 | 46,XY[20] | - | - | None | 0 | ||
| 3 | 86/M | RCMD | Int-1 | 46,XY[20] | - | - | None | 0 | ||
| 4 | 76/F | NA | Int-1 | 47,XX,+8[3]/46,XX[47] | + | - | None | 1 | ||
| 5 | 54/F | NA | Int-1 | 46,XX,t(6;7)(q21;p22),del(20)(q11)[9]/46,XX[11] | + | - | None | 1 | ||
| 6 | 37/M | RCMD | Int-1 | 46,XY[20] | - | - | CD56, CD13 | 2 | ||
| 7 | 77/M | RA | Int-1 | 45,X,-Y[4]/46,X,-Y,+8[16] | + | - | CD117 | 2 | ||
| 8 | 78/M | RA | Low | 46,XY,del(20)(q11)[2]/46,XY[18] | + | - | CD117 | 2 | ||
| 9 | 84/M | RCMD | Int-1 | 46,XY[20] | + | - | CD13 | 2 | ||
| 10 | 79/M | RA | Int-1 | 46,XY,del(20)(q11)[10]/47,XY,del(20)(q11), +22[1]/46,XY[9] | - | - | CD56, CD113 | 2 | ||
| 11 | 75/F | RCMD | Int-1 | 47,XX,+8[17]/47,XX,+8,del(13)(q12q14)[3] | + | - | CD4 | 2 | ||
| 12 | 75/F | RA | Int-1 | 46,XX,t(1;2)(q?41;q?31)[18]/46,XX[2] | + | - | CD56, CD15 | 3 | ||
| 13 | 82/M | MDS-U | Low | 46,XY[20] | - | - | CD11b, CD117, CD133 | 3 | ||
| 14 | 80/M | RCMD | Int-1 | 46,XY[20] | + | + | CD117 | 3 | ||
| 15 | 81/M | RCMD | Int-1 | 46,XY,del(20)(q11)[20] | + | - | CD56, CD15 | 3 | ||
| 16 | 74/F | RCMD | Int-1 | 46,XX[20] | - | - | CD56, CD15, CD33 | 3 | ||
| 17 | 78/M | RCMD | Int-1 | 46,XY,inv(6)(p23;q15)[20] | + | - | CD13, CD117 | 3 | ||
| 18 | 39/F | RA | Low | 46,XX[20] | + | - | CD56, CD15, CD33 | 4 | ||
| 19 | 69/M | RCMD | Int-2 | 46,XY,+1,der(1;7)(q10;p10)[6]/45,X,-Y[2]/46,XY[9] | - | - | CD4, CD13, CD117, CD133 | 4 | ||
| 20 | 85/F | RCMD | Int-1 | 46XX,add(18)(p11)[19]/46XX,i(17)(q10),add(18)(p11)[1] | + | + | CD13, CD117 | 4 | ||
| 21 | 75/M | RCMD | Int-1 | 47,XY,+13[2]/46,XY[18] | + | - | CD13, CD117, CD133 | 4 | ||
| 22 | 57/F | RCMD | NA | No metaphases | + | - | CD15, CD33, CD117, CD133 | 5 | ||
| 23 | 48/M | RA | Int-1 | 47,XX,+8[20] | + | - | CD4, CD13, CD15, CD133 | 5 | ||
| 24 | 73/F | RA | Low | 46,XX[20] | - | + | CD4, CD11b, CD15, CD33 | 5 | ||
| 25 | 70/M | RCMD | Int-1 | 46,XY,+1,der(1;7)(q10;p10)[9]/46,XY[11] | + | + | CD4, CD13, CD117 | 5 | ||
| 26 | 61/M | RCMD | Int-2 | 46,XY,+1,der(1;7)(q10;p10)[10]/46,X,del(Y)(q12),+1,der(1;7)(q10;p10)[5] | + | + | CD4, CD11b, CD13, CD15 | 6 | ||
| 27 | 64/F | RA | Int-2 | 45,XX,-7,inc[3]/46,XX[17] | + | + | CD56, CD11b, CD15, CD33, CD117 | 7 | ||
NA indicates not applicable; Int, intermediate.
Plus signs indicate that percentage data were outside the RRs, and minus signs indicate that percentage data were within the RRs. Two NA cases (nos. 4 and 5) could not be classified because they had no morphologic abnormalities despite having chromosomal aberrations.